| Literature DB >> 30223584 |
Andrzej Miskiewicz1, Piotr Ceranowicz2, Mateusz Szymczak3,4, Krzysztof Bartuś5, Paweł Kowalczyk6.
Abstract
This review deals with various microbiological activities of ionic liquids, which constitute the first anti-infective defense against multi-drug-resistant bacteria-with a particular emphasis placed on medicine and pharmacology. The quoted data on the biological activity of ionic liquids including their antimicrobial properties (depending on the type of a cation or an anion) and are discussed in view of possible applications in nosocomial infections. Dedicated attention is given to finding infections with the Klebsiella pneumoniae New Delhi strain, Acinetobacter baumannii, and Enterococcus species, which are responsible for the induction of antibiotic resistance in intensive care units. Diagnosis and treatment using current antibiotics is a significant problem in hospital care, and the relevant burden on the health systems of the European Union member states induces the search for new, effective methods of treatment. Ionic liquids, due to their antibacterial effect, can be considered topical and general medications and may provide the basis for treatment to eliminate the antibiotic resistance phenomenon in the future. At present, the number of infections with resistant pathogens in hospitals and outpatient clinics in the European Union is growing. In 2015⁻2017, a significant incidence of respiratory and bloodstream infections with bacteria resistant to antibiotics from the 3rd generation group of cephalosporins, glycopeptides, and carbapenems were observed. The paper presents examples of synthesized bifunctional salts with at least one pharmaceutically active ion in obtaining a controlled release, controlled delivery, and biological impact on the pathogenic bacteria, viruses and fungi. The ionic liquids obtained in the presented way may find applications in the treatment of wounds and infections.Entities:
Keywords: Ionic liquids; antimicrobial effect; drug resistance
Mesh:
Substances:
Year: 2018 PMID: 30223584 PMCID: PMC6163946 DOI: 10.3390/ijms19092779
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1The chart summarizes main properties and their current applications of ionic liquids [8,9,10,11].
Figure 2Examples of cations in ionic liquids.
Figure 3Cations and anions of ionic liquids with their structure and an exemplary type of substituent. X means: Tetrafluoroborate –BF4−, trifluoroacetate CF3COO−, chloride –Cl−, hexafluoroantimonate –SbF6−, bis trifluoro sulfonyl imide –(CF3SO2)2N−, trifluorosulfane acetate –CF3SO3− [46,47].
Morbidity, number of hospitalizations and mortality due to selected bacterial infections with priority pathogens causing blood stream infections in people in the European Union countries in 2012–2017.
| Pathogen | Strain Characteristics | Number Of Detected Cases | Confirmed Cases Of ICU* Acquired Infections | Percentage Of Selected Strains Detected Is Surgical Site Infections | Drug Resistance | Comorbidity Index | Mortality | Reference |
|---|---|---|---|---|---|---|---|---|
|
| Nosocomial | 712 | 541 | 4.1% | 3rd eneration cephalosporins | 2.8 | 18% | [ |
| MDR+ | 3.9 | 26% | [ | |||||
|
| New Delhi | 1367 | 561 | 4.7% | 3rd generation Cephalosporins, Meropenem, Vancomycin | 6.4 | 72% | BIOCONTAM Unit |
|
| PAPI+ | 2 269 | 516 | 7.1% | Aminoglycosides, Gyrase inhibitors, Penicillin with β-lactamase inhibitor | 4.8 | 38% | [ |
|
| MRSA | 1996 | 631 | 38.1% | β-lactams, Lincosamides, Fluoroquinolones | 4.5 | 30% | [ |
|
| VRE | 492 | 340 | 20.4% | Vancomycin, Teicoplanin | 2.7 | 43.1% | [ |
| other | ESBL+ | 1367 | 479 | 3.3% | β-lactams, 3rd generation Cephalosporins, Trimethoprim/Sulfomethaxazole | 1.8 | 18.2% | BIOHAZ team, EARS-Net |
Antibiotic resistance was developed on the basis of data from hospital intensive care units and swabs taken from nonhealing wounds from surgical sites. Data were compiled on the basis of surveillance reports, annual epidemiological reports, antimicrobial resistance, and healthcare-associated infections. ECDC, EARS-Net, EFSA, BIOHAZ team and BIOCONTAM Unit: Antimicrobial resistance annual report (Stockholm, April 2015; doi: 10, 2900/6928) [75,80,85,87,89,90].
Listing of bacterial priority strains including S. aureus, Enterococcus species, K. pneumoniae, Enterobacteriaceae and P. aeruginosa, antibiotic resistance mechanisms and ionic liquids showing the best effect in the treatment of infections.
| Bacterial Strain | Strain Specification | Antibiotic Resistance Chracteristics | Ionic Liquid | Principal Mechanism of Action | MIC [Mmol L−1] | MBC [Mmol L−1] | References |
|---|---|---|---|---|---|---|---|
|
| HA-MRSA | MGEs+ | [C8mim][Cl] | Collapse of liposomes, localized perforations in dioleoylphosphatidylcholine bilayers | 116 | 170 | [ |
| MZ100 | SCC | [C4C1Im] | Perforation of dipalmitoylophosphatidylcholine with phospholipid bilayers [Tf2N], isotopic substitution of hydrogen | 188 | 250 | ||
|
| |||||||
| BORSA |
| [Chol][Cl] | 125 | 188 | |||
| USA300 |
| Di-But C6 | Leakage of cellular liposomes, | 1000 | |||
| CA-MRSA |
| Di-Hex C6 | 8 | 4 | |||
| ATCC25923 | NorA efflux pump | BTFLA | 23 | 43 | |||
| MDRSA | |||||||
| 1,3-dialkiloimidazolinum | Docking complex formation with tubulin FtsZ PC190723, | 2.12 | 6.14 | ||||
| [C1C14 pi][BF4 ]2 | 5.6 | 19.3 | |||||
| [Phpi][BF4] | 1.2 | 4.8 | |||||
| [(C2)2(C1)2(C1)2 | >100 | 342 | |||||
| ATCC6538 | C16M1Im][Br] | 23 | NA | ||||
| [C16M1Im][Amp]* | 7.9 | 7.9 ** | |||||
|
| COM12-15 | VRE | [C12Py] | De-stabilising effect on lipid structure | 8.1 | 8.1 ** | [ |
| [C18Py] | 8.5 | 8.5 ** | |||||
| [EMIm+Tf2N-] | Mismatch between ionic liquid cations and lipids in the layer | 16.8 | 34.6 | ||||
| [C12Im] | Long-tail cation mediated cytotoxicity, electrostatic signature interacting with peptidoglycan | 7.1 | 7.1 ** | ||||
| [C18Im] | 8.1 | 8.1 ** | |||||
| [BMIm+Cl-] | 7.5 | 7.5 ** | |||||
| Ag+C3H5N2- | 5.7 × 10−10 | 5.7 × 10−10 ** | |||||
|
| ATCC4352 | Metallo-β-lactamse-1 | [C2mim][Cl] | Inhibition of acetylcholineesetrase | 178 | 263 | [ |
| [CBP] | Interaction with phosphatidic acid, apoptosis triggering | 13 | NA | ||||
| [CPB][AMP] * | Antibiotic donor | 4.7 | 9 ** | ||||
| [C16M2Im][Br] | Interaction with cytoskeleton protein subunits | 15 | NA | ||||
| [C16M2Im][AMP] * | Antibiotic donor | 7.8 | 7.8 ** | ||||
|
| W3110 | OXA-48 carbapenemase | [Chol]+ Thre | Interaction with biomembranes surrounding cellular organelles | 31.3 | 62.5 | [ |
| [Chol]+ Pro | 46.9 | 62 | |||||
| β-lactamase encoding genes | Di-But C10 | Decreased flexural rigidity and reduced interfacial tension between the bilayer and ionic liquid, lysis of bacterial outer membrane | 40 | 40 ** | |||
| Di-Hex C10 | 8 | 8 ** | |||||
| PTLFS | 91 | 470 | |||||
| [(C2)2 | 12.5 | 39.5 | |||||
| [C2pi][BF4] | 2.38 | 11.8 | |||||
| [C2C1C14pi][I] | >50 | 185 | |||||
|
| PA14 | OM-proteins | Di-Hex C10 | Coagulation of cytoplasm | 9 | 20 | [ |
| ATCC 27853 | MDEP | 1,3 dialkiloimidazolinum | Asymetric absorbtion of ionic liquid cation by leaflets of phospholipid bilayer | 18.4 | 45.8 | ||
| BMP-NTf2 | 24 | 65.6 | |||||
| HMIM-Cl | 12.4 | 61.5 | |||||
| [P(C14H29)(C6H13)3]+ | 8.4 | 20 | |||||
| (ZnCl2)2 - BZBN | 12.3 | 31 |
The mechanism of action of ILs and the minimum inhibitory concentration, and the minimum bactericidal concentration are given. * ILs, which belong to APIs, were identified. ** The inhibitory concentration is equivalent to the bactericidal concentration [38,50,51,66,69,80,86,89,91,92,93,94,95,96,97,98,99,100,101,103].